User login

Enter your username and password here in order to log in on the website:
Choose language: English | Deutsch

Infront up-to-date–
news, dates, events



FIX EMEA Trading Conference 2020
Exhibitions and Congresses

The EMEA Trading Conferenceis Europe’s largest one-day electronic trading event. The event will cover the most pressing issues facing the institutional trading community and provide a neutral platform for buy-side, sell-side, exchanges, vendors and regulators to share their ideas on how the community can continue to collaborate. Designed to appeal to all asset classes, the agenda will maintain a great balance of topics across multiple asset classes.

The event will be held virtually. Further information will follow shortly.

11th AM Tech Day
Exhibitions and Congresses

AM TECH DAY is the European market event dedicated to the impact of technological innovation on the asset management industry, gathering asset managers, wealth managers, asset owners, insurers and FinTechs. For its 11th year, the event will be held on 13 October at the Palais Brongniart, Paris.

The health crisis has made it more vital than ever to communicate, talk and work online, effectively boosting the value of all tools that can do this in a fast and secure way. It has also spurred their adoption throughout the asset management industry with the early adopters effectively providing a stress test for the sector.

At the same time, technologies continue to improve, giving professional investors a better handle on the key issues affecting sustainable development and helping them adopt best practice in transparency, equity and security.

Now more than ever, the asset management industry has the means and the opportunity to reinvent itself.

Meet Infront there: Palais Brongniart, 16 Place de la Bourse, at 10:00.

19th COPS Usertreff
Exhibitions and Congresses

As in previous years, COPS invites to their annual COPS user meeting this year from 22 to 23 October 2020 at the Seehotel Rust in Rust on Neusiedlersee.

The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.

As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.

On site, our colleagues Catherine Hanek, Achim Beisswenger and Sebastian Ullrich will be available for a lively exchange of ideas.

You can find further information here...

SIPUGday 2020
Exhibitions and Congresses

The SIPUGday focuses since the start on market data and related technologies, services and products in the front, back and middle office. Regulations and their impact on data are also a topic for our audience.

Infront and vwd will be represented on site by Ivo Bieri, Managing Director Switzerland. He will be happy to inform you about the advantages for you of the merger of the two companies in the future. We look forward to a lively exchange with you!

October 27, 2020

Marriott Hotel,
Neumühlequai 42
8006 Zurich


DKF 2020, 10. D-A-CH Kongress für Finanzinformationen
Exhibitions and Congresses

We will again be represented at the DKF this year and look forward to your visit to our stand.

Further information will be available here soon or on the official DKF 2020 website.

Quantalys Inside 2020
Exhibitions and Congresses

Further information will be available shortly here or under Quantalys Inside 2020.

 Latest news on markets, economy and companies


Business Wire


08.07.2020 Mynewsdesk: Athera reports last patient visit for Phase 2 trial in STEMI patients

Athera Biotechnologies AB, a Swedish biopharmaceutical developer of therapeutic antibodies, announced that the last patient visit has been completed in their Phase 2 study with ATH3G10, a new candidate drug for prevention of heart failure following an acute myocardial infarction. The study completed recruitment in March by including 82 patients with STEMI and aims for top-line results to be presented in 2020, in accordance with earlier plans.


The study is designed to evaluate if treatment with ATH3G10 significantly decreases the risk of heart failure following myocardial infarction in comparison to placebo. The study targeted inclusion of approximately 80 patients with acute myocardial infarction and high risk to develop heart failure. Treatment effect is measured by Magnetic Resonance Imaging (MRI) scans that correlate with development of heart failure. A total of 15 hospitals in Sweden, Denmark and The Netherlands participated in the study.


“We are so proud and grateful to be working with such an outstanding study organization. Despite huge challenges from the Coronavirus pandemic during recent months, the team’s efforts in patient follow-up have been outstanding. We have now received MRI scans from all planned follow-up patient visits, meaning that we have a good data set to evaluate the treatment effects,” says James Hall, CEO of Athera. “We owe the teams at the acute cardiology units and at the MRI units gratitude for their outstanding dedication and active conduct of the study. This has been one of the quickest trials to recruit in this patient population in recent years”.


The results will be evaluated after the database is locked and are planned to be communicated at a scientific congress later this year.



Diese Pressemitteilung: wurde via Mynewsdesk versendet. Weitere Informationen finden Sie im Athera Biotechnologies AB:


=== Pressekontakt ===


James Hall


Athera Biotechnologies AB

Sankt Eriksgatan 117, 4th floor





Telefon: +46705775300



=== Pressekontakt ===


Carina Schmidt


Athera Biotechnologies AB

Sankt Eriksgatan 117, 4th floor





Telefon: +46 (0)76-1938190



=== Athera Biotechnologies AB ===


About ATH3G10


ATH3G10 is a first-in-class fully human antibody to target phosphorylcholine (PC), the head group of oxidized phospholipids (oxPLs), an epitope on damaged or stressed cells. The candidate is initially being developed for patients with a large ST-elevation myocardial infarction (STEMI) who are at high risk of heart failure. Tissue from infarcted myocardium that has suffered an injury has large amounts of exposed PC, indicating that the body is not clearing away damaged cells effectively. Non-resolving inflammation can lead to cardiac remodelling and heart failure within months. The 5-year mortality in heart failure is 50%—worse than many cancers.





About Athera Biotechnologies AB


The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of cardiovascular disease. In addition to an intravenous formulation of ATH3G10 for use in acute settings, Athera is developing a subcutaneous version for longer-term, repeat dosing in different conditions. Major shareholders in Athera are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB. For more information:













Subscribe to our free newsletter and you will receive the latest information about our products and solutions.